6,678 trials
Febrile Neutropenia
Primary: Mean (SD) Doripenem Pharmacokinetic Volume of Distribution Parameter in Febrile Neutropenic Patients — 36.7; 49.9; 43.9 Liters
Diabetes Mellitus, Type 1
Primary: Change From Baseline in Hemoglobin A1c (HbA1c) at Week 24 Endpoint — -0.48; -0.43 percentage of glycosylated hemoglobin — p=0.6692
Opioid Dependence · HIV
Primary: Opiate Positive Urines With Missing Urines Coded as Positive at Week 12. — 14; 5 participants
Hypertension
Primary: Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at the Study End Point (12 Weeks) — -16.8; -10.6 mm Hg
Congestive Heart Failure
Primary: Long-term Effectiveness of the COROX Over-the-wire (OTW) Steroid in Providing Biventricular Pacing — 1.3 Threshold Voltage
Peripheral Vascular Diseases
Primary: Efficacy: Primary Patency at Three Years — 24.2; 25.9 percentage of subjects
Asthmatic Smokers · Non-asthmatic Smokers
Primary: Sputum Neutrophil Percentages — 86.00; 72.53; 89.33; 79.84 percentage of neutrophils
Inflammation
Primary: Mean Change in Level: Week 16-baseline in Ena-78 — -111.2 pg/ml — p=0.15
Human Immunodeficiency Virus (HIV)
Primary: Time-weighted Mean Change From Baseline Plasma HIV-RNA. — -2.59; -2.69; -2.39 log copies/mL
Healthy Skin
Primary: Erythema Rating Scale — 0.6; 0.7 units on a scale
Diabetes Mellitus, Type 2 · Endothelial Dysfunction
Primary: Left Ventricular Torsion Defined as Change in Ventricular Mid-wall Rotation (°) Measured by Cine-Cardiac Magnetic Resonance (CMR) Imaging With Tagging, Before and After…
Ankylosing Spondylitis
Primary: Number of Patients Using Healthcare Resources in the 48 Weeks Before and During Treatment — 6; 4; 8; 4 patients — p=0.743
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) at Steady-State (After 3rd Dose) — 193.33; 165.70 mcg/mL
Metabolic Syndrome · Hypertension
Primary: Change in MAP During Placebo — -0.9; 2.7; -7.9 mmHg
Fever
Primary: Child Temperature (Degrees C)Over 6 Hours — 38.5; 37.2; 36.9 degrees Celcius — p=<0.001